CIK 0001370053
- Non-accelerated filer
- Smaller reporting company
ANAPTYSBIO, INC
Sign in to watch- Ticker
- ANAB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203828755
- Phone
- +1 858-362-6295
- Business address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
- Former names
- ANAPTYSBIO INC, ANAPTYS BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $249,372
- in 1 filing, $249K under 10b5-1 plans
Net −$249,372. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-06 | Marquet Magda Director | Grant or award · Stock Option (right to buy) | +10,600 | 10,600 | ||
| 2023-01-06 | Marquet Magda Director | Grant or award · Restricted Stock Unit | +3,900 | 3,900 | ||
| 2023-01-06 | LOUMEAU ERIC J COO, General Counsel | Grant or award · Stock Option (right to buy) | +60,530 | 60,530 | ||
| 2023-01-06 | LOUMEAU ERIC J COO, General Counsel | Grant or award · Restricted Stock Unit | +22,180 | 22,180 | ||
| 2023-01-06 | Lizzul Paul F. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +67,070 | 67,070 | ||
| 2023-01-06 | Lizzul Paul F. Chief Medical Officer | Grant or award · Restricted Stock Unit | +24,580 | 24,580 | ||
| 2023-01-06 | Hamill Laura Director | Grant or award · Stock Option (right to buy) | +10,600 | 10,600 | ||
| 2023-01-06 | Hamill Laura Director | Grant or award · Restricted Stock Unit | +3,900 | 3,900 | ||
| 2023-01-06 | FENTON DENNIS M Director | Grant or award · Stock Option (right to buy) | +10,600 | 10,600 | ||
| 2023-01-06 | FENTON DENNIS M Director | Grant or award · Restricted Stock Unit | +3,900 | 3,900 | ||
| 2023-01-06 | Faga Daniel Interim CEO | Grant or award · Stock Option (right to buy) | +194,900 | 194,900 | ||
| 2023-01-06 | Faga Daniel Interim CEO | Grant or award · Restricted Stock Unit | +71,400 | 71,400 | ||
| 2022-09-14 | Lizzul Paul F. Chief Medical Officer | Grant or award · Restricted Stock Unit | +12,000 | 12,000 | ||
| 2022-09-14 | LOUMEAU ERIC J COO, General Counsel | Grant or award · Restricted Stock Unit | +12,000 | 12,000 | ||
| 2022-09-14 | MULROY DENNIS Chief Financial Officer | Grant or award · Restricted Stock Unit | +12,000 | 12,000 | ||
| 2022-08-08 | LOUMEAU ERIC J COO, General Counsel | Sale | −523 | $25.00 | $13K | 0 |
| 2022-06-23 | MULROY DENNIS Chief Financial Officer | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2022-06-23 | LOUMEAU ERIC J COO, General Counsel | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2022-06-23 | Lizzul Paul F. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2022-06-08 | LOUMEAU ERIC J COO, General Counsel | Exercise or conversion | +2,500 | $14.02 | $35K | 3,023 |
Page 21 of 27 · 522 trades